I rotter med plasmakoncentrationer 6 gange højere end i klinikken medfører sunitinib- behandling under organogenesen en forøget forekomst af skeletforandringer hos fostrene, fortrinsvis forsinket ossifikation af bryst - og lændehvirvlerne.
Sunitinib treatment in rats during organogenesis resulted in developmental effects at ≥ 5 mg/ kg/ day consisting of increased incidence of foetal skeletal malformations, predominantly characterized as retarded ossification of thoracic/ lumbar vertebrae and occurred at plasma exposure levels 6-fold higher than is observed in clinic.